ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis CEO Sees Big Potential In Biosimilars

ZURICH -(Dow Jones)- Novartis AG (NVS) Chief Executive Joe Jimenez said Tuesday he sees potential in the market for biosimilars, cheaper versions of expensive and complex medicines made from biological matter. "This is a market that is relatively small today, but we expect that by 2020 this could be a 15 to 20 billion dollars segment of the generics business," Jimenez told analysts in a call. "Novartis is uniquely positioned in biosimilars because we have the scientific and medical expertise of a pharmaceutical company and the commercial expertise of a generics company," he said. Novartis has its own generics unit, Sandoz. Biosimilars are imitations of biotech drugs, ones that are basically interchangeable with a previously approved biologic but because of the inherent complexity of the products cannot be termed identical. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
09/02/201516:30:00Novartis Closer to Selling Copy of Amgen's Neupogen
09/02/201516:22:00Court Decision Could Allow Novartis To Sell Copy of Amgen's Neupogen...
09/02/201516:16:00Court Decision Could Allow Novartis To Sell Copy of Amgen's Neupogen
09/02/201502:00:00Amgen to Help Develop Novartis's Pipeline of Alzheimer's Drugs
09/01/201502:32:00Novartis Gets EU Approval For Skin Cancer Drugs Tafinlar, Mekinist
08/27/201519:20:00FDA Approves New Amgen Cholesterol Drug
08/21/201509:26:00Correction to Glaxo Sells Rights to Auto-Immune Drug to Novartis
08/21/201509:19:00Glaxo Sells Rights to Auto-Immune Drug to Novartis -- Update
08/21/201506:20:00Glaxo Sells Drug Rights to Novartis
08/21/201506:04:00Glaxa Sells Rights to Auto-Immune Drug to Novartis
08/21/201502:19:00GSK to Sell Rights in Ofatumumab for Auto-Immune Indications...
08/20/201503:03:00Novartis Gets EU Approval For Skin Cancer Treatment Odomzo
08/10/201509:15:00Active Equities to Watch in the Healthcare Sector -- AstraZeneca...
07/29/201508:10:07GSK Posts Sharp Fall in Profit
07/29/201507:29:46Novartis Spins Off Three Pipeline Drugs Into New Company
07/22/201519:45:14ADRs End Lower; National Bank of Greece, Petrobras Trade Actively
07/21/201518:40:12ADRs End Mixed; Infosys Rises
07/21/201515:19:03Novartis Can Sell Copycat of Amgen's Neupogen in September, Court...
07/21/201502:42:34Novartis Pressured by Dollar Strength -- Update
07/21/201502:40:10Novartis Pressured by Dollar Strength

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad